Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Phio Pharmaceuticals ( (PHIO) ) just unveiled an announcement.
On November 3, 2025, Phio Pharmaceuticals announced positive results from its Phase 1b trial of INTASYL PH-762 for cutaneous squamous cell carcinoma, with one patient achieving 100% tumor clearance, another over 90%, and a third over 50% at Day 36. The Safety Monitoring Committee reviewed the safety data favorably, noting no dose-limiting toxicities or adverse effects, underscoring the potential of PH-762 as a non-surgical treatment option, which could enhance Phio’s position in the oncology therapeutics market.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.
To see Spark’s full report on PHIO stock, click here.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL gene silencing technology. The company’s lead clinical program, PH-762, targets the PD-1 gene to enhance immune cells’ ability to kill cancer cells, offering a potential non-surgical treatment for skin cancers such as cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
Average Trading Volume: 125,010
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.74M
For a thorough assessment of PHIO stock, go to TipRanks’ Stock Analysis page.